Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Egbert F. Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares, Jose M. Pacheco, Bob T. Li, David Planchard, Christina S. Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai Cheng, Qi Yan, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne
Topics & Concepts
MedicineTrastuzumabCohortInternal medicineClinical endpointOncologyLung cancerCancerClinical trialBreast cancerHER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPeptidase Inhibition and Analysis